about
CO2 laser therapy of the Bartholin's gland cyst: surgical data and functional short- and long-term results.Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients.Chemotherapy in elderly patients with gynecological cancer.Thrombotic thrombocytopenic purpura during pregnancy versus imitator of preeclampsia.BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).Invasive vulvar carcinoma and the question of the surgical margin.CO2 laser treatment for Bartholin gland abscess: ultrasound evaluation of risk recurrence.HPV induced triple neoplasms: a case report.Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells.Immune effects of trastuzumabGene expression profile of patients with Mayer-Rokitansky-Küster-Hauser syndrome: new insights into the potential role of developmental pathways.HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.Guidelines of how to manage vesicovaginal fistula.Monoclonal antibodies in gynecological cancer: a critical point of view.The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions.Solitary gastric recurrence from ovarian carcinoma: a case report and literature review.Urethral coitus in a patient with a microperforate hymen.Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.Vaginal reconstruction with the Abbè-McIndoe technique: from dermal grafts to autologous in vitro cultured vaginal tissue transplant.Role of chemotherapy in the management of vulvar carcinoma.Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.Olaparib, PARP1 inhibitor in ovarian cancer.Monoclonal antibodies therapies for ovarian cancer.Surgical treatment of an isolated omental cervical cancer recurrence: report of a case and review of the literature.Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.Past, present and future strategies of immunotherapy in gynecological malignancies.Laparoscopically guided minilaparotomy: a minimally invasive approach for the treatment of gynaecologic diseases in morbidly obese patients.Minimal invasive approaches for large ovarian cysts: a careful choice.Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.Intraperitoneal paclitaxel as consolidation treatment in ovarian cancer patients: a case control study.Ovarian cancer, diagnosed with PET, with bilateral inguinal lymphadenopathy as primary presenting sign.Post radical hysterectomy urinary incontinence: a prospective study of transurethral bulking agents injection.Anterior colporrhaphy plus inside-out tension-free vaginal tape for associated stress urinary incontinence and cystocele.Effects of unilateral ovariectomy on female fertility outcome.Mechanical bowel preparation before gynecologic laparoscopy: a randomized, single-blind, controlled trial.When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer.Urologic function and urodynamic evaluation of urinary diversion (Rome pouch) over time in gynecologic cancers patients.A comparative analysis of serum and serum-free media for generation of clinical grade DCs.Vaginoplasty using autologous in vitro cultured vaginal tissue in a patient with Mayer-von-Rokitansky-Kuster-Hauser syndrome.
P50
Q31111545-25CC84FD-168B-498F-B96C-726ADA4C48AAQ33384306-19913E4D-7D39-4D49-9558-C09B0CF2B155Q33410185-DC103381-7FDC-42CC-B316-0C0BE473EE81Q33425102-DC562F61-18AF-4066-B1C3-3288806BA35EQ33456583-D47D6A67-7A4E-4EFB-A0C2-0052348DC372Q33931275-C76D91B3-9F53-4C58-9855-AF4703A72A75Q34574086-6B595D6F-DEAA-47D2-AA88-1197AB3AFB10Q34995034-2513EA89-6BB2-4094-8103-76E94046AAE0Q35024484-A74DB825-A3D1-44BB-A6CA-AC6C2AC73F3BQ35057976-C5F362BB-8FB8-446B-B6EA-E93DB1032C66Q35114881-0AFEFE9B-364F-4BE2-96E1-31C6B4A4BBB4Q35556207-E33FAAEB-70B6-4CF1-BBEA-4A8E5F229E69Q35615288-C7B8AF16-DB99-4327-A653-5F2BA5723CD7Q35659915-7F9631EF-AEB5-4E44-8AB8-117FC7387119Q35684064-899684F8-BF09-423C-95C7-1694566C33B0Q36805494-944C7704-653C-4331-ACDE-51881EBA6510Q37250568-F946B67F-F556-40A0-863F-2512CC818787Q37294314-5F7D47C4-7067-4F86-92EB-FD1B341800C1Q37638386-003DDD19-BE39-4373-8D43-44A4BD52CF46Q37847094-0E3BA3F4-2656-4456-A8EE-2DC31EDC11CAQ37878049-8257167A-3349-40C6-8662-BBEC35E12627Q37953105-4B85DD80-E992-423F-8876-3EC5A9E00A2FQ38025738-B0F37828-40F1-4E75-A897-028992A99F3EQ38078400-DCD6EF71-99F2-4438-873D-B430DF0B38A4Q38213889-CBC31E5A-A1E1-44D5-B604-70393437B536Q38380255-25EA3248-521F-423F-8BBF-50BE5E74DF58Q39560771-5E2FD3C7-3261-4AEF-BF85-2C878CB4672EQ43641157-523259CF-885B-49CD-A7C8-ADF8EB9D56E4Q44181351-4A816B52-C24C-4E7E-9F6E-C4510EF3D6D1Q44839641-51EFFE14-974E-49D1-BFCC-993EBE437496Q45098795-1AA887DE-B68F-4BE6-BF1D-2022D7447B0DQ46771780-57006DB5-5F42-45AD-ADEC-7662A9C5FA22Q47274785-4E43E059-1336-4F84-8616-76CFFA31B834Q47655581-0C808B9C-9550-480A-AF57-E2AEE814474CQ47822785-C280559A-E182-4168-BEE2-3C59A1181B99Q48456134-31DD41F9-386C-4E7E-BB5F-6A3407DC1FABQ48960901-8040F9F3-E5C9-4685-AE11-7948B8F81F46Q50937679-B9F50B29-CDCF-4D5D-B1FA-700F048B5486Q50971466-99072DE2-E545-442A-9DA5-E5BDD9B173B4Q51021015-33A47B3E-13D4-4A5E-BEC9-59E56266333F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Filippo Bellati
@ast
Filippo Bellati
@en
Filippo Bellati
@es
Filippo Bellati
@nl
Filippo Bellati
@sl
type
label
Filippo Bellati
@ast
Filippo Bellati
@en
Filippo Bellati
@es
Filippo Bellati
@nl
Filippo Bellati
@sl
prefLabel
Filippo Bellati
@ast
Filippo Bellati
@en
Filippo Bellati
@es
Filippo Bellati
@nl
Filippo Bellati
@sl
P106
P1153
6507297829
P21
P31
P496
0000-0002-2036-9951